natamycin: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by dreye

natamycin Introduction (What it is)

natamycin is an antifungal medication.
In eye care, it is most commonly used as prescription eye drops for certain fungal infections of the cornea.
It is also used outside ophthalmology in some food and agricultural settings to help control fungal growth.
In clinical practice, it is discussed most often in the context of fungal keratitis (a fungal corneal infection).

Why natamycin used (Purpose / benefits)

natamycin is used to treat infections caused by fungi. In ophthalmology, the main problem it aims to solve is fungal keratitis, an infection of the cornea (the clear front “window” of the eye). Fungal keratitis can threaten vision because it can cause corneal inflammation, ulceration (an “open sore” on the cornea), scarring, and in severe cases structural damage.

Potential benefits of natamycin in eye care include:

Targeted antifungal activity for certain organisms that can infect the cornea (especially filamentous fungi, depending on the case).
Local delivery to the ocular surface when used as topical drops, which helps concentrate therapy where many corneal infections occur.
A steroid-sparing role early in care: in suspected fungal keratitis, clinicians often focus first on controlling infection before considering medications that reduce inflammation but can worsen some infections. (Exactly how inflammation is managed varies by clinician and case.)
Vision preservation goals: by treating the infection, the aim is to reduce the risk of complications like corneal scarring or perforation, recognizing that outcomes depend on severity, timing, and organism.

Natamycin does not correct vision like glasses or contact lenses. Its role is infection control, with the broader goal of protecting corneal clarity and eye integrity.

Indications (When ophthalmologists or optometrists use it)

Typical scenarios where natamycin may be considered include:

Suspected or confirmed fungal keratitis, particularly when clinical findings and risk factors suggest a fungal cause
Corneal ulcer with features concerning for fungus, such as feathery-edged infiltrates (hazy inflammatory spots) or satellite lesions, when judged relevant by the clinician
History of corneal trauma involving plant or soil material, which can increase fungal risk
Contact lens–associated keratitis when fungal infection is on the differential diagnosis (the list of possible causes)
Persistent keratitis not responding to antibacterial therapy, where clinicians broaden evaluation to include fungi
Culture- or smear-supported fungal infection, after corneal scraping or laboratory testing, when available
Co-management settings where optometrists help identify and triage corneal ulcers and ophthalmologists direct antifungal treatment and follow-up

The decision to use natamycin depends on the clinical exam, local patterns of disease, test results (when available), and the treating clinician’s judgment.

Contraindications / when it’s NOT ideal

Natamycin is not suitable for every red or painful eye. Situations where it may be avoided or may not be the preferred approach include:

Known hypersensitivity/allergy to natamycin or formulation components (for example, preservatives), if present
Non-fungal causes of keratitis (such as bacterial, viral, or sterile inflammatory keratitis), where other treatments may be more appropriate
Infections deeper inside the eye (for example, endophthalmitis), where topical surface drops may not reach adequate internal concentrations; approach varies by clinician and case
Deep corneal infections where drug penetration is a concern; clinicians may consider different agents, adjunctive therapy, or procedural options depending on depth and severity
Inadequate diagnostic clarity: when the presentation is ambiguous, clinicians may prioritize diagnostic testing and broad initial management rather than relying on a single agent
When a different antifungal is chosen based on organism identification, local availability, medication tolerance, or clinician preference (varies by clinician and case)

“Not ideal” does not mean “never used.” It means the clinician may reassess whether natamycin fits the likely organism, infection location, and overall treatment plan.

How it works (Mechanism / physiology)

Mechanism of action (high level)

natamycin is a polyene antifungal. Polyenes interact with ergosterol, a key component of many fungal cell membranes. By binding to ergosterol and disrupting membrane function, natamycin interferes with fungal cell integrity and growth. This makes it useful against susceptible fungi on the ocular surface and within infected corneal tissue.

Relevant eye anatomy and tissues

Cornea: The primary target in fungal keratitis. The cornea has layers (epithelium, stroma, endothelium). Many infectious ulcers involve the epithelium and stroma, where inflammation can reduce transparency.
Tear film and ocular surface: Topical drops first mix with the tear film, then contact the corneal surface.
Anterior chamber (inside the eye): Topical natamycin is generally intended for surface/anterior corneal infection; deeper internal infections require different strategies.

Onset, duration, and reversibility

Onset: Antifungal effects are not typically “instant.” Clinical improvement depends on organism type, infection depth, and how early therapy begins (varies by clinician and case).
Duration: Treatment courses for corneal fungal infections are often measured in weeks rather than days, but the exact duration varies by clinician and case.
Reversibility: The medication’s effects stop after it is discontinued, but tissue changes from infection—such as scarring—may persist even after the fungus is controlled. Final visual impact depends on scar location and density.

If a concept like “reversibility” doesn’t neatly apply the way it might for a temporary diagnostic drop, the closest relevant point is that natamycin treats infection, while any structural corneal changes caused by the infection may be longer-lasting.

natamycin Procedure overview (How it’s applied)

natamycin is not a surgical procedure. It is a medication most often administered as topical ophthalmic drops under clinician supervision for suspected or confirmed fungal keratitis. A typical high-level workflow may look like this:

Evaluation / exam
– History (symptoms, contact lens wear, trauma, agricultural exposure, prior medications)
– Slit-lamp exam to assess the corneal epithelium and stroma, ulcer size, depth, and any anterior chamber inflammation
– Measurement of visual acuity and basic eye health checks
Preparation (diagnostic planning)
– Clinicians may perform or arrange corneal scraping for smear and culture when indicated and feasible
– Photographs or drawings may be used to document ulcer size and location for comparison over time
Intervention (medication use)
– natamycin drops may be started when fungal keratitis is suspected or confirmed, often with a dosing schedule determined by severity (details vary by clinician and case)
– Additional medications may be used to manage pain, inflammation, or co-infection risk, depending on findings (varies by clinician and case)
Immediate checks
– Short-interval reassessment may be used to confirm the infection is stabilizing and to monitor for complications such as thinning of the cornea
Follow-up
– Follow-up frequency depends on severity and response
– Treatment may be adjusted based on clinical response and laboratory identification of the organism (when available)
– If scarring or irregular astigmatism remains after infection control, clinicians may later discuss optical rehabilitation options (glasses, contact lenses, or surgical approaches, depending on the case)

This overview is intentionally general; specific regimens and monitoring plans are individualized.

Types / variations

In eye care, “types” and variations of natamycin usually refer to formulation and clinical context, rather than multiple brand-new drug classes.

Common variations and practical distinctions include:

Topical ophthalmic suspension
natamycin is commonly formulated as a suspension (tiny particles in liquid), which typically requires shaking before use (follow product labeling).
Suspensions can temporarily blur vision because of their physical properties.
Preserved vs preservative-free considerations
Some patients have ocular surface sensitivity to preservatives; availability varies by region and manufacturer.
Commercial vs compounded preparations (context-dependent)
In some settings, access and compounding practices influence which antifungal drops are used. Compounded options may be considered when specific agents are needed or supply is limited (varies by material and manufacturer).
Therapeutic role variations
Empiric therapy: started when fungal keratitis is suspected clinically, before organism confirmation.
Targeted therapy: refined after smear/culture results identify a fungus and susceptibility patterns, when testing is available.
Adjunctive care (not “types” of natamycin, but common pairing contexts)
natamycin may be used alongside supportive measures and close monitoring. Additional agents are chosen based on the clinical picture (varies by clinician and case).

Pros and cons

Pros:

Targets fungal pathogens that can cause corneal ulcers, helping address an otherwise difficult-to-treat infection category
Topical delivery can concentrate therapy on the cornea and ocular surface
Widely recognized in ophthalmic practice as an option for fungal keratitis management, especially when filamentous fungi are a concern (organism patterns vary by region)
Can be integrated into a stepwise care plan that includes diagnostics, monitoring, and escalation if needed
Familiar to many cornea specialists and emergency eye care pathways
Avoids systemic exposure when used only topically, though local side effects can still occur

Cons:

Not effective for non-fungal causes of keratitis (bacterial, viral, allergic, or sterile inflammatory conditions)
Penetration limitations may reduce utility for very deep corneal infection or intraocular infection; alternatives may be considered (varies by clinician and case)
Can cause temporary blurred vision and ocular surface discomfort because it is often a suspension
May cause stinging, redness, tearing, or irritation in some users (tolerance varies)
Requires frequent dosing and close follow-up in many cases, which can be challenging in day-to-day life (specific schedules vary)
Access, cost, and availability can vary across regions and pharmacies (varies by material and manufacturer)

Aftercare & longevity

With antifungal eye treatment, “aftercare” generally refers to monitoring, adherence, and protecting the ocular surface while the cornea heals. The course and “longevity” of results depend less on the bottle itself and more on the infection’s severity and the cornea’s recovery.

Key factors that commonly influence outcomes include:

Severity at presentation
Larger, deeper, or centrally located corneal ulcers tend to require longer monitoring and can have more lasting visual impact.
Time to appropriate therapy
Earlier recognition and targeted treatment can matter in infectious keratitis, but response still varies by organism and host factors (varies by clinician and case).
Adherence and dosing practicality
Antifungal regimens may be intensive. Missed doses can complicate infection control, though the real-world impact varies by case.
Follow-up and re-evaluation
Serial exams help clinicians track ulcer size, corneal thinning, inflammation, and healing patterns, and to adjust therapy.
Ocular surface health
Dry eye, eyelid disease (blepharitis), and exposure issues can affect healing and comfort.
Comorbidities and immune status
Conditions that affect healing (for example, diabetes or immunosuppression) can influence recovery (varies by clinician and case).
Residual scarring and corneal irregularity
Even after infection control, the cornea may heal with scar tissue or irregular shape, which can affect vision quality. Visual rehabilitation options are chosen case-by-case.

Because fungal keratitis can be unpredictable, clinicians often emphasize ongoing observation until the cornea is stable, then later evaluate how much visual function returns and what optical correction is needed.

Alternatives / comparisons

Alternatives to natamycin depend on what is being treated. If the condition is not fungal keratitis, the comparison shifts toward therapies for bacterial, viral, or noninfectious disease. When fungal keratitis is the concern, alternatives typically involve other antifungal agents and supportive strategies.

High-level comparisons include:

natamycin vs other topical antifungals (e.g., amphotericin B, azole antifungals such as voriconazole)
Different antifungals have different organism coverage, formulations, tolerability, and penetration characteristics.
Clinicians may choose based on suspected organism (yeast vs filamentous fungi), ulcer depth, local availability, and lab results when available (varies by clinician and case).
Topical therapy vs systemic (oral/IV) antifungals
Many corneal infections are approached with topical drops first.
Systemic therapy may be considered in selected situations (for example, severe disease, scleral involvement, or risk of spread), but choices are individualized (varies by clinician and case).
Medication vs procedure (corneal interventions)
If the cornea is thinning significantly, perforation risk is present, or infection is uncontrolled, procedural options may be considered (for example, tissue adhesive, therapeutic contact lens, or corneal transplantation).
Procedures do not replace the concept of antimicrobial therapy; they often address structure and healing while infection management continues.
Observation/monitoring alone
For suspected microbial keratitis, “watchful waiting” is generally not the central strategy because untreated infection can progress. However, diagnostic uncertainty can lead to short-interval reassessment while tests are pending (varies by clinician and case).
Supportive care vs antifungal therapy
Lubrication and pain control may help comfort, but they do not treat fungal infection. Supportive measures are usually adjuncts rather than substitutes.

The most appropriate comparator depends on the confirmed organism, location and depth of infection, and patient-specific factors.

natamycin Common questions (FAQ)

Q: Is natamycin an antibiotic?
No. natamycin is an antifungal medication, meaning it targets fungi rather than bacteria. Antibiotics treat bacterial infections, while antifungals are used when fungi are suspected or confirmed.

Q: What eye condition is natamycin most associated with?
In ophthalmology, natamycin is most commonly associated with fungal keratitis, a fungal infection of the cornea. This condition can present with pain, light sensitivity, tearing, blurred vision, and a visible corneal ulcer.

Q: Does natamycin hurt or burn when used as eye drops?
Some people experience stinging, irritation, tearing, or a gritty sensation after instilling drops. Discomfort can come from the medication, the preservative system, or the inflamed ocular surface itself. Symptom intensity varies by individual and by the underlying condition.

Q: How long does it take to work, and how long might treatment last?
Antifungal treatment response is typically measured over days to weeks, not minutes. The overall course often depends on organism type, ulcer depth, and healing response. Duration varies by clinician and case.

Q: Will natamycin blur vision?
It can. natamycin is commonly a suspension, and suspended particles can temporarily blur vision after dosing. In addition, the infection itself often reduces visual clarity until the cornea heals.

Q: Can I drive or use screens after putting in natamycin drops?
Some people notice temporary blur or light sensitivity after dosing or due to the corneal condition. Whether driving is safe depends on functional vision at that time and local legal requirements. Screen use is usually possible, but comfort may be limited by light sensitivity or irritation (varies by case).

Q: Is natamycin “safe”?
Like any medication, natamycin has potential side effects and risks. When prescribed, clinicians weigh expected benefits against risks such as irritation, allergy, and the risk of undertreating a different cause of keratitis. Safety considerations are individualized.

Q: How much does natamycin cost?
Cost varies widely by region, pharmacy pricing, insurance coverage, and whether a product is commercially available or compounded. Your clinic or pharmacy may be able to provide a general range for your area. Out-of-pocket cost can also change over time due to supply factors.

Q: Can I wear contact lenses while using natamycin?
In active keratitis or corneal ulceration, contact lens wear is commonly paused to reduce irritation and contamination risk, but decisions vary by clinician and case. If contact lenses are used at all during treatment, it is typically under close supervision. Lens type and hygiene factors can also influence decisions.

Q: What happens if the cornea scars after the infection clears?
Corneal scarring can leave lasting blur or glare, especially if it is central. After the infection is controlled and the cornea stabilizes, clinicians may discuss vision rehabilitation options such as updated glasses, specialty contact lenses, or surgical approaches depending on the scar and corneal shape (varies by clinician and case).